Shares of Endo Pharmaceuticals Holdings Inc. slipped Monday after the company said regulators want more information about a new version of its pain drug Opana ER before they will allow Endo to start selling it.
All News, Video and Posts related to SECTOR: Health Care
Popular Posts:
- Doc's Talk: PA rejects IDF offer to help probe Bil'in protester death
- Quidel projects 52 percent drop in 4Q revenue
- Infinity Pharma gains ground on analyst upgrade
- Cardinal Health will buy Zuellig Pharma of China
- Inhibitex shares sink after drug trial announced